These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38352162)

  • 1. Hyaluronic acid turnover controls the severity of cerebral cavernous malformations in bioengineered human micro-vessels.
    Yordanov TE; Keyser MS; Enriquez Martinez MA; Esposito T; Tefft JB; Morris EK; Labzin LI; Stehbens SJ; Rowan AE; Hogan BM; Chen CS; Lauko J; Lagendijk AK
    APL Bioeng; 2024 Mar; 8(1):016108. PubMed ID: 38352162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling.
    Zhou Z; Tang AT; Wong WY; Bamezai S; Goddard LM; Shenkar R; Zhou S; Yang J; Wright AC; Foley M; Arthur JS; Whitehead KJ; Awad IA; Li DY; Zheng X; Kahn ML
    Nature; 2016 Apr; 532(7597):122-6. PubMed ID: 27027284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting miR-27a/VE-cadherin interactions rescues cerebral cavernous malformations in mice.
    Li J; Zhao Y; Choi J; Ting KK; Coleman P; Chen J; Cogger VC; Wan L; Shi Z; Moller T; Zheng X; Vadas MA; Gamble JR
    PLoS Biol; 2020 Jun; 18(6):e3000734. PubMed ID: 32502201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential angiogenesis function of CCM2 and CCM3 in cerebral cavernous malformations.
    Zhu Y; Wu Q; Xu JF; Miller D; Sandalcioglu IE; Zhang JM; Sure U
    Neurosurg Focus; 2010 Sep; 29(3):E1. PubMed ID: 20809750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDC42 Deletion Elicits Cerebral Vascular Malformations via Increased MEKK3-Dependent KLF4 Expression.
    Castro M; Laviña B; Ando K; Álvarez-Aznar A; Abu Taha A; Brakebusch C; Dejana E; Betsholtz C; Gaengel K
    Circ Res; 2019 Apr; 124(8):1240-1252. PubMed ID: 30732528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism.
    Ren AA; Snellings DA; Su YS; Hong CC; Castro M; Tang AT; Detter MR; Hobson N; Girard R; Romanos S; Lightle R; Moore T; Shenkar R; Benavides C; Beaman MM; Müller-Fielitz H; Chen M; Mericko P; Yang J; Sung DC; Lawton MT; Ruppert JM; Schwaninger M; Körbelin J; Potente M; Awad IA; Marchuk DA; Kahn ML
    Nature; 2021 Jun; 594(7862):271-276. PubMed ID: 33910229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease.
    McDonald DA; Shenkar R; Shi C; Stockton RA; Akers AL; Kucherlapati MH; Kucherlapati R; Brainer J; Ginsberg MH; Awad IA; Marchuk DA
    Hum Mol Genet; 2011 Jan; 20(2):211-22. PubMed ID: 20940147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic MAP3K3 mutation defines a subclass of cerebral cavernous malformation.
    Weng J; Yang Y; Song D; Huo R; Li H; Chen Y; Nam Y; Zhou Q; Jiao Y; Fu W; Yan Z; Wang J; Xu H; Di L; Li J; Wang S; Zhao J; Wang J; Cao Y
    Am J Hum Genet; 2021 May; 108(5):942-950. PubMed ID: 33891857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro characterization of the angiogenic phenotype and genotype of the endothelia derived from sporadic cerebral cavernous malformations.
    Zhu Y; Wu Q; Fass M; Xu JF; You C; Müller O; Sandalcioglu IE; Zhang JM; Sure U
    Neurosurgery; 2011 Sep; 69(3):722-31; discussion 731-2. PubMed ID: 21471841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebral cavernous malformations are driven by ADAMTS5 proteolysis of versican.
    Hong CC; Tang AT; Detter MR; Choi JP; Wang R; Yang X; Guerrero AA; Wittig CF; Hobson N; Girard R; Lightle R; Moore T; Shenkar R; Polster SP; Goddard LM; Ren AA; Leu NA; Sterling S; Yang J; Li L; Chen M; Mericko-Ishizuka P; Dow LE; Watanabe H; Schwaninger M; Min W; Marchuk DA; Zheng X; Awad IA; Kahn ML
    J Exp Med; 2020 Oct; 217(10):. PubMed ID: 32648916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low fluid shear stress conditions contribute to activation of cerebral cavernous malformation signalling pathways.
    Li J; Zhao Y; Coleman P; Chen J; Ting KK; Choi JP; Zheng X; Vadas MA; Gamble JR
    Biochim Biophys Acta Mol Basis Dis; 2019 Nov; 1865(11):165519. PubMed ID: 31369819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunofluorescence of Cell-Cell and Cell-Extracellular Matrix Adhesive Defects in In Vitro Endothelial CCM Model: Juxtacrine Role of Mutant Extracellular Matrix on Wild-Type Endothelial Cells.
    Manet S; Vannier D; Bouin AP; Lisowska J; Albiges-Rizo C; Faurobert E
    Methods Mol Biol; 2020; 2152():401-416. PubMed ID: 32524568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTORC1 Inhibitor Rapamycin Inhibits Growth of Cerebral Cavernous Malformation in Adult Mice.
    Li L; Ren AA; Gao S; Su YS; Yang J; Bockman J; Mericko-Ishizuka P; Griffin J; Shenkar R; Alcazar R; Moore T; Lightle R; DeBiasse D; Awad IA; Marchuk DA; Kahn ML; Burkhardt JK
    Stroke; 2023 Nov; 54(11):2906-2917. PubMed ID: 37746705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebral cavernous malformations: from CCM genes to endothelial cell homeostasis.
    Fischer A; Zalvide J; Faurobert E; Albiges-Rizo C; Tournier-Lasserve E
    Trends Mol Med; 2013 May; 19(5):302-8. PubMed ID: 23506982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis.
    Akers AL; Johnson E; Steinberg GK; Zabramski JM; Marchuk DA
    Hum Mol Genet; 2009 Mar; 18(5):919-30. PubMed ID: 19088123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCM1-ICAP-1 complex controls β1 integrin-dependent endothelial contractility and fibronectin remodeling.
    Faurobert E; Rome C; Lisowska J; Manet-Dupé S; Boulday G; Malbouyres M; Balland M; Bouin AP; Kéramidas M; Bouvard D; Coll JL; Ruggiero F; Tournier-Lasserve E; Albiges-Rizo C
    J Cell Biol; 2013 Aug; 202(3):545-61. PubMed ID: 23918940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformations.
    Choi JP; Wang R; Yang X; Wang X; Wang L; Ting KK; Foley M; Cogger V; Yang Z; Liu F; Han Z; Liu R; Baell J; Zheng X
    Sci Adv; 2018 Nov; 4(11):eaau0731. PubMed ID: 30417093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KLF4 is a key determinant in the development and progression of cerebral cavernous malformations.
    Cuttano R; Rudini N; Bravi L; Corada M; Giampietro C; Papa E; Morini MF; Maddaluno L; Baeyens N; Adams RH; Jain MK; Owens GK; Schwartz M; Lampugnani MG; Dejana E
    EMBO Mol Med; 2016 Jan; 8(1):6-24. PubMed ID: 26612856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EndMT contributes to the onset and progression of cerebral cavernous malformations.
    Maddaluno L; Rudini N; Cuttano R; Bravi L; Giampietro C; Corada M; Ferrarini L; Orsenigo F; Papa E; Boulday G; Tournier-Lasserve E; Chapon F; Richichi C; Retta SF; Lampugnani MG; Dejana E
    Nature; 2013 Jun; 498(7455):492-6. PubMed ID: 23748444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebral cavernous malformation protein CCM1 inhibits sprouting angiogenesis by activating DELTA-NOTCH signaling.
    Wüstehube J; Bartol A; Liebler SS; Brütsch R; Zhu Y; Felbor U; Sure U; Augustin HG; Fischer A
    Proc Natl Acad Sci U S A; 2010 Jul; 107(28):12640-5. PubMed ID: 20616044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.